GEn1E Lifesciences
PrivateLast Round
Grant
Oct 24, 2023
Total Funding Raised
$4M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
GEn1E Lifesciences is a biotechnology company that accelerates the development of next-generation immunomodulatory therapies for rare and inflammatory diseases through an innovative drug development platform that leverages artificial intelligence to create novel therapeutics rapidly.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Medical AI, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
GEn1E Lifesciences Comparables
Compare GEn1E Lifesciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Genesis Molecular AI | 83% | |
| Recursion Pharmaceuticals | 79% | |
| Junction Bioscience | 78% |
GEn1E Lifesciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Oct 24, 2023 | ||||
| VC Round | Dec 6, 2022 | ||||
| Seed | Mar 31, 2020 | ||||
| Seed | Aug 21, 2019 |
GEn1E Lifesciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| StartX | Seed |
| Khosla Ventures | Seed, VC Round |
| Gaingels | VC Round |
| Inflect Health | Seed, VC Round |
| Public Health Emergency Medical Countermeasures Enterprise | Grant |
| Clear Ventures | Seed, VC Round |
| Y Combinator | Seed, VC Round |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 48% MoM, reaching 3.4K.
- May 13, 2026
Monthly visitors increased 65% MoM.
GEn1E Lifesciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about GEn1E Lifesciences's valuation, stock price, and market status.
Is GEn1E Lifesciences a public or private company?
GEn1E Lifesciences is a private company.
What is the current stock price of GEn1E Lifesciences?
GEn1E Lifesciences is a private company with no public stock price. No recent secondary market data is available.
How much is GEn1E Lifesciences worth (valuation)?
Valuation information for GEn1E Lifesciences is not publicly available.
Can I buy GEn1E Lifesciences stock?
GEn1E Lifesciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was GEn1E Lifesciences's last funding round?
GEn1E Lifesciences's most recent funding round was Series A on December 21, 2022.
Who are the main investors in GEn1E Lifesciences?
Key investors in GEn1E Lifesciences include Khosla Ventures, Inflect Health, Clear Ventures, Y Combinator, SV Latam Capital.
Will GEn1E Lifesciences IPO soon?
No public IPO plans have been announced for GEn1E Lifesciences.
How can I track GEn1E Lifesciences secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor GEn1E Lifesciences's secondary market activity and sign up for updates.